MediWound has spent three straight conference calls telling investors that 2026 would be a back-loaded year. The third-quarter report is where that promise either starts to look credible or begins to look like a stretch. With just $4.6 million of revenue booked in the first half against a reaffirmed full-year target of $24 million to $26 million, the company needs roughly $19 million to $21 million over the final two quarters. That leaves very little room for another timing excuse.
Wall Street is looking for revenue of about $7.6 million, up 40.5% from $5.4 million a year ago and more than double the $3.1 million reported last quarter. The Street expects a loss of $0.66 per share, narrower than the $0.77 loss in the second quarter but well wide of the $0.24 loss in the year-ago period. The more telling figure is the full-year consensus of $24.11 million, which sits right at the bottom of management's range. Analysts are effectively accepting the guidance while declining to give the company much benefit of the doubt. Simple arithmetic shows the problem: even if the company hits the third-quarter number, the fourth quarter would need to deliver something in the $12 million to $14 million range, a level MediWound has not approached recently.
The swing factor is the new VeriCell master service agreement, signed in the second quarter and tied to a 10-year BARDA contract worth up to $197 million. Management said revenue recognition would begin in the second half, and this is the first report where that should show up. Any visible contribution, along with more clarity on economics that have so far been undisclosed, would go a long way toward validating the back-half ramp. A quiet quarter on that front, or more talk of components awaiting FDA feedback and negotiation, would challenge it. The other pillar is NexoBrid's US commercial business, which posted record revenue and hospital unit sales last quarter as the count of ordering burn centers climbed to about 80. Continued growth in that figure would show that commercial demand, and not just government funding, is driving the story.
Margins and cash deserve equal attention. Gross margin fell to 10.9% last quarter on what management described as a one-time hit from scaling up the facility. A rebound toward the low 20s, where margins sat a year earlier, would support that explanation. A margin that stays depressed would suggest the costs are more stubborn than advertised. Cash dropped to $36 million at the end of June after a $20 million first-half burn, and R&D spending is expected to stay elevated through the value trial. If burn holds near $10 million a quarter, the balance sheet becomes a live question well before the trial's interim reassessment, which has already slipped to the end of the first quarter of 2027. Commercial supply from the expanded facility has also moved to the second half of 2027. Investors will want both timelines held steady, along with confirmation that the diabetic foot ulcer Phase 2 and pressure ulcer studies are starting this quarter as planned.
The market has turned cautious. Sentiment has slipped from slightly bullish before the last report to modestly bearish now. The stock is down 4.8% since then, trailing the S&P 500 by about two percentage points. At $13.39 it sits below its 200-day moving average of $15.21 and in the upper half of a post-earnings range of $11.80 to $14.41. That entire range sits below the prior quarter's $13.54 to $16.13 band, a sign of a lower expectations bar.
Ultimately, this report hinges on whether second-half revenue is actually materializing. A solid third quarter with real VeriCell revenue and recovering margins would keep the full-year guidance believable. Another light quarter would push nearly the entire year's credibility onto a single fourth-quarter result.